Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?

被引:16
|
作者
Piccardo, Arnoldo [1 ]
Puntoni, Matteo [2 ]
Ferrarazzo, Giulia [1 ]
Foppiani, Luca [3 ]
Bottoni, Gianluca [1 ]
Altrinetti, Vania [1 ]
Treglia, Giorgio [4 ,5 ]
Naseri, Mehrdad [1 ]
Dib, Bassam [1 ]
Cabria, Manlio [1 ]
Trimboli, Pierpaolo [4 ,5 ]
Massollo, Michela [1 ]
Giovanella, Luca [4 ,5 ]
机构
[1] Galliera Hosp, Nucl Med Dept, Genoa, Italy
[2] Galliera Hosp, Clin Trial Unit, Off Sci Director, Genoa, Italy
[3] Galliera Hosp, Internal Med, Genoa, Italy
[4] Oncol Inst Southern Switzerland, Dept Nucl Med, Bellinzona, Switzerland
[5] Oncol Inst Southern Switzerland, PET CT Ctr, Bellinzona, Switzerland
关键词
Differentiated thyroid cancer; TSH stimulation; Radioactive remnant ablation; Prognosis; STAGING SYSTEM; DTC PATIENTS; RISK; CARCINOMA; THERAPY; MANAGEMENT; GUIDELINES; LEVEL; TSH;
D O I
10.1007/s00259-018-3955-x
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Current guidelines recommend thyroid hormone withdrawal (THW) of 3-4 weeks before radioiodine remnant ablation (RRA) of differentiated thyroid carcinoma (DTC). We aimed to evaluate (1) the reliability of a shorter THW (i.e., 14 days) to achieve adequate TSH levels (i.e., 30 mU/l), (2) the association between length of THW and response to therapy, and (3) the potential association between pre-ablation TSH levels and patients' outcome. Methods After thyroidectomy, all patients started LT4 therapy, which was subsequently discontinued in order to perform RRA. Patients were broken down into two groups according to the length of THW: group A, 2 weeks of THW, and group B, 3-4 weeks of THW. We used clinical, biochemical, and imaging data to evaluate patients' outcome. By means of univariate and multivariate analysis, including main DTC prognostic factors, we assessed the impact of THW length and TSH levels on patients' outcome. Results We evaluated 222 patients, 85 of whom were treated with RRA after a THW period of 2 weeks (group A). All other 137 patients underwent RRA after 3-4 weeks THW (group B). At the time of RRA all patients presented TSH levels >= 30 MU/l After a median follow-up time of 3.4 years, we found 183 patients (82%) with excellent response to treatment and 39 patients (18%) showing incomplete response. Kaplan-Meier response to therapy curves showed that ablation-Tg, tumor size, and lymph node status were significantly associated with prognosis: no associations were found between THW length, TSH levels, and prognosis. Multivariate Cox model showed that only ablation-Tg was significantly associated with treatment response. Conclusions Prior to RRA, a short 2-week THW is an effective method to stimulate TSH levels. No difference in terms of incomplete response to treatment was observed between DTC patients prepared for RRA with a short THW and those with the long THW.
引用
收藏
页码:1218 / 1223
页数:6
相关论文
共 50 条
  • [41] Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid: a comparison of ablation success with different activities of radioiodine (I-131)
    Marin Prpic
    Nina Dabelic
    Josip Stanicic
    Tomislav Jukic
    Milan Milosevic
    Zvonko Kusic
    Annals of Nuclear Medicine, 2012, 26 : 744 - 751
  • [42] Radioiodine remnant ablation in low-risk differentiated thyroid cancer: the "con" point of view
    Lamartina, Livia
    Cooper, David S.
    ENDOCRINE, 2015, 50 (01) : 67 - 71
  • [43] Strategy for radioiodine ablation in thyroid cancer with naive levothyroxine patients
    Tamez-Perez, Hector E.
    Delgadillo, Enrique
    Soni-Duque, David
    Tamez-Pena, Alejandra L.
    GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, 2019, 178 (10) : 859 - 859
  • [44] Indication for radioiodine remnant ablation in differentiated thyroid cancer patients: does 2018 Italian consensus change anything?
    R. Forleo
    N. Fralassi
    F. Maino
    M. Capezzone
    L. Brilli
    T. Pilli
    S. Cantara
    M. G. Castagna
    Journal of Endocrinological Investigation, 2021, 44 : 139 - 144
  • [45] Low-Risk Differentiated Thyroid Cancer and Radioiodine Remnant Ablation: A Systematic Review of the Literature
    Lamartina, Livia
    Durante, Cosimo
    Filetti, Sebastiano
    Cooper, David S.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (05): : 1748 - 1761
  • [46] Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation
    Vrachimis, A.
    Schober, O.
    Riemann, B.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2012, 51 (03): : 67 - 72
  • [47] Outcomes comparison of thyroxine withdrawal of 2 weeks and 3 weeks for radioiodine remnant ablation of differentiated thyroid carcinoma
    Wang, Yueqi
    Huang, Rui
    Li, Lin
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [48] Radioiodine remnant ablation in low-risk differentiated thyroid cancer: the “con” point of view
    Livia Lamartina
    David S. Cooper
    Endocrine, 2015, 50 : 67 - 71
  • [49] A Randomized Noninferiority Trial To Determine the Optimum Dose of Radioiodine for Remnant Ablation in Differentiated Thyroid Cancer
    Bal, C. S.
    Chandra, P.
    Kumar, A.
    Dwivedi, S. N.
    ENDOCRINE REVIEWS, 2010, 31 (03) : S1675 - S1675
  • [50] Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen
    Borget, I.
    Remy, H.
    Chevalier, J.
    Ricard, M.
    Allyn, M.
    Schlumberger, M.
    De Pouvourville, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (08) : 1457 - 1463